Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals beat expectations on both the top and bottom line in the second fiscal quarter of 2026, with preliminary results reported on Aug. 3, 2026. Revenue rose 32.4% to about $219.1 million, above the roughly $205.3 million consensus by 6.7%, while adjusted EPS of $0.54 topped the $0.42 estimate by 27.8% even as it fell 40.7% from $0.91 a year ago. Gross profit came in at about $185.4 million, with gross margin near 85%, and operating cash flow was negative about $4.8 million. Net product sales, the largest line, increased 4.9% to roughly $165.7 million; within that, Qelbree climbed 15.1% to about $89.2 million, and royalty, licensing and other revenue jumped 141.3% to about $18.0 million. Consensus for the next period calls for EPS of $0.66 on revenue of $217.8 million.